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The purpose of this thesis was to further elucidate the effects 
and site of action of the cholinergic drugs on dopaminergic neurons in 
rat striatum with the use of certain biochemical parameters which 
provide an index of dopaminergic function. The short term accumulation 
of Dopa (3,4-dihydroxyphenylalanine), the immediate precursor of dopamine, 
following inhibition of Dopa decarboxylase was used as an in vivo 
estimate of tyrosine hydroxylase activity. Dopac (dihydroxyphenyl- 
acetic acid), a metabolite of dopamine, was measured to provide an 
index of changes in the physiological activity of nigro-neostriatal 
dopamine neurons (Fig. 1). 
This study investigated: 
(1) The effects of a variety of cholinergic and anticholinergic drugs 
on tyrosine hydroxylase activity, responsible for the conversion 
of tyrosine to Dopa in the dopamine synthetic pathway (Fig. 1). 
(2) The possible site of action of these drugs, whether presynaptic 
or a more complex neuronal feedback mechanism (Fig. 2). 
(3) The possibility that an experimental animal model of Parkinson’s 
Disease might respond differently from normals to the same cholin¬ 











































The Extrapyramidal System: 
The extrapyramidal system is responsible for control and fine 
tuning of motor activity. The basal ganglia, a primary component of 
this'system, includes the corpus striatum (caudate nucleus, putamen, 
and globus pallidus), the first two known collectively as the neo¬ 
striatum, and the amygdaloid nucleus.^ The substantia nigra, the 
other major component of the extrapyramidal system, consists of the 
pars compacta and the zona reticulata. The nigrostriatal dopaminergic 
fiber system extends from the pars compacta of the substantia nigra 
to the ipsilateral striatum and appears to be topographically arranged. 
Each fiber has approximately 500,000 boutons to make synaptic contacts 
with striatal cells. Mid-brain lesions destroying the substantia nigra 
result in signs of degeneration in between 65% and .100% of the striatal 
29 
boutons. Stimulation of the substantia nigra increases release of 
29 
striatal dopamine and causes an increase in dopamine biosynthesis as 
a result of an activation of tyrosine hydroxylase.^ Approximately 
80% of the total dopamine (DA) and homovanillic acid (HVA), a metabolite 
of dopamine, in the mammalian brain is found in the caudate nucleus 
and putamen. The distribution of the dopamine synthesizing enzymes 
29 
tyrosine hydroxylase and Dopa decarboxylase is similar. 
29 
Drugs Affecting Striatal Dopaminergic Activity: 
Drugs which increase dopamine or dopamine effects at receptor 
sites in the striatum may act: (1) directly - as dopamine (or Dopa 
which is converted to dopamine) or apomorpnine, a specific dopamine 
receptor agonist; (2) indirectly - as amphetamines and amantidine 
' 
4 
which cause dopamine to be released from nerve terminals; and (3) as 
anticholinergics and antihistamines which may act by decreasing the 
cholinergic component of a dopaminergic - cholinergic balance in the 
striatum, or some may act by inhibiting the reuptake of dopamine into 
synaptosomes, making more dopamine available in the synaptic cleft. 
Drugs which decrease dopamine or dopamine effects at receptor 
sites may act by: (1) blocking dopamine receptor activity - as the 
butyrophenones, like haloperidol, and most phenothiazines; (2) inhibit¬ 
ing synthesis of dopamine - as a-methyl-p-tyrosine; (3) inhibiting 
dopamine storage and depleting synaptic vesicles - as reserpine; and 
(4) degeneration of the nigrostriatal pathway - as caused by lesions 




It is now well established that the basic abnormality in Parkin¬ 
son's Disease is a striatal dopamine deficiency. The most common 
etiologies are either idiopathic or post-encephalitic. The majority 
of the latter cases are thought to be a late sequela of encephalitis 
lethargica, a disease caused by Von Economo's virus during the 1918 
to 1926 pandemic. Other possible causes include senile arteriosclerosis, 
chronic manganese poisoning, tumor, and a reversible Parkinsonian-like 
syndrome sometimes resulting from the use of neuroleptic drugs such 
as reserpine, most phenothiazines, and the butyrophenones. In all but 
the neuroleptic-induced syndrome, the primary pathological abnormality 

5 
is degeneration of the dopamine containing cells in the pars compacta 
29 
of the substantia nigra projecting to the striatum. In these patients, 
29,31,56 
striatal levels of dopamine and HVA are markedly decreased, as 
are the activities of the dopamine synthesizing enzymes, tyrosine hy- 
56 
droxylase and Dopa decarboxylase. In addition, a positive correlation 
exists between the degree of nigral cell loss, the degree of striatal 
56 
dopamine deficiency , and the severity of the Parkinsonian symptoms 
29 
of akinesia, rigidity, and tremor. That dopamine levels must fall 
by 50% or more to manifest the disease clinically, suggests that milder 
degrees of striatal dopamine deficiency can be compensated for func- 
29 
tionally. The reversible drug-induced Parkinson s-like syndrome 
produced to varying degrees by most of the antipsychotics is a mani¬ 
festation of the dopamine receptor blocking ability of these drugs 
rather than of an absolute striatal dopamine deficiency. Consistent 
with this is the observation that treatment with L-Dopa, which is 
converted to dopamine by Dopa decarboxylase, produces marked symptomatic 
improvement in Parkinson's Disease where there is an absolute dopamine 
deficiency, but is of little value in treating the drug-induced 
23 
Parkinsonian syndrome where symptoms are due to receptor blockade. 
Optimal therapy for Parkinson's Disease at present involves the use of 
L-Dopa in conjunction with carbidopa, a peripheral Dopa decarboxylase 
9 
inhibitor. With the combined use of these drugs less Dopa needs to 
be administered, since more enters the brain, and fewer side-effects 
15 23,45 
are experienced from peripheral conversion of Dopa to dopamine. * 
Although L-Dopa acts by replacing the deficient neurotransmitter, 

6 
dopamine, it does not affect the course of Parkinson's Disease, in 
that there is continued degeneration of the nigrostriatal dopamine 
29 
neurons. Dopamine levels in the striatum of Parkinson's patients 
can be increased 5 to 8 times with L-Dopa treatment, and levels of its 
30 
metabolite, HVA, are increased by even more. HVA accumulates 
throughout the brain, wherever there is Dopa decarboxylase activity, 
but dopamine accumulates only in areas of dopaminergic innervation, 
29 31 
such as the striatum. * This could be due to uptake and storage 
of the dopamine in the dopaminergic nerve terminals or to a depot source, 
such as 3-0-methyldopa, which also increases in L-Dopa treated 
29 31 
patients. * The former, however, is more likely, as 3-0-methyldopa 
increases throughout the brain, like HVA, rather than locally, as 
with dopamine.^ 
Another phenomenon observed in Parkinson's patients and in animals 
with lesions destroying the nigrostriatal dopamine neurons may be the 
development of denervation supersensitivity, an increase in dopamine 
receptor sensitivity to the effects of dopamine.^^ Although patients 
on L-Dopa show no difference with respect to maximal therapeutic bene¬ 
fit, patients with severe akinesia react more sensitively to a single 
intravenous dose of L-Dopa than do patients with mild akinesia. 
Patients on high doses of L-Dopa and animals after injection of high 
doses of L-Dopa, develop abnormal choreiform movements due to the 
increased dopamine levels, which can be eliminated by decreasing the 
29 
doses of L-Dopa. During chronic treatment with L-Dopa, patients 
often develop an increased sensitivity to both the therapeutic effects 
and the choreiform side effects. This effect may also be due to 

7 
denervation supersensitivity, resulting from continued degeneration 
29 
of the dopaminergic neurons. 
29 
Effects of Increased Dopaminergic Activity: 
Increased dopaminergic activity manifests itself as locomotor 
hyperactivity and stereotyped motor behavior. This increased activity 
could be produced either (1) by facilitation of excitatory systems or 
(2) by removal of inhibitory influences upon such systems (disinhibi- 
tion). The latter is most widely held to be correct. In unanesthe¬ 
tized animals, the spontaneous firing rate of most caudate cells is 
decreased by locally applied dopamine and by electrical stimulation 
of the substantia nigra which increases release of striatal dopamine. 
It is possible that the enhancement of motor activity by dopamine 
agonists is due to elimination of normal striatal inhibitory impulses 
2 9 
which modify the "primitive motor patterns of the globus pallidus." 
Post-Synaptic Dopamine Receptor Activation and Neuronal Feedback: 
Most of the antipsychotics, the phenothiazines like chlorpro- 
mazine and the butyrophenones like haloperidol, are potent dopamine 
receptor blockers. Their ability to increase the firing rate of dopa¬ 
mine neurons in the pars compacts of the substantia nigra'*’ and to 
increase synthesis and turnover J of dopamine is presumed to be due 
to a neuronal feedback mechanism, since the effect is dependent upon 
impulse flow in dopamine neurons. Dopamine agonists, direct and 
indirect, have the opposite effect upon dopamine neurons. The agonists 

8 
result in decreases in the synthesis and release of dopamine, an effect 
24 
which can be blocked by the dopamine receptor blockers. 
Presynaptic Dopamine Receptors: 
The firing of dopaminergic neurons, and the synthesis and release 
of dopamine, appears to be affected not only by a postsynaptic feedback 
mechanism, but also by dopamine receptors located on the terminals of 
the dopamine neuron itself. Support for this comes in the findings: 
(1) that dopamine receptors have been found on the cell body and den¬ 
drites of dopamine neurons and, therefore, may also be present along 
the axon and nerve terminals, and (2) that the presynaptic and the 
postsynaptic dopamine receptors appear to respond differently to some 
10 
drugs. 
In normal impulse flow, the action of synaptic dopamine is ter¬ 
minated primarily by reuptake into nerve terminals rather than by 
degradation of the neurotransmitter. Increasing the firing rate of 
dopaminergic neurons, as in other types of nerves, results in a stimulus 
dependent increase in synthesis and release of dopamine. Unlike in 
other neurons, however, cessation of impulse flow in dopaminergic 
neurons, induced either pharmacologically or by axotomy, leads to a 
paradoxical increase in tyrosine hydroxylase activity and in dopamine 
10 34 48 
synthesis. * ’ Presynaptic dopamine receptors are postulated to 
be responsible, since the interruption of impulse flow excludes feedback 
neuronal regulation. The suggested mechanism is a decrease in the 
release of dopamine secondary to interruption of impulse flow, leading 
. 
9 
to a decrease in synaptic cleft dopamine available to react with the 
presynaptic receptors. 
The pool of dopamine in the nerve terminal is probably controlled 
by a balance of release, reuptake, and synthesis. Tyrosine hydroxylase 
activity appears to be subject to end-product inhibition by this neu- 
tronal dopamine pool, such that decreased utilization leads to an in¬ 
creased neuronal dopamine pool, which then inhibits tyrosine hydroxy¬ 
lase activity and dopamine synthesis. This end-product inhibition 
appears to be dependent upon calcium influx into the neuron, which in 
turn may depend upon stimulation of presynaptic dopamine receptors. 
Lesions of the dopamine neurons or pharmacological treatment with GBL 
(y-butyrolactone), leads to cessation of impulse flow in the nigro- 
neostriatal dopamine neurons, with a concomittant cessation of dopamine 
release and calcium influx. The result is an activation of tyrosine 
hydroxylase with an increase in synthesis and in the neuronal dopamine 
pool to which the tyrosine hydroxylase is no longer responsive, possi¬ 
bly because of the decreased influx of calcium. The postulated role 
of the presynaptic receptors is to allow calcium influx and return 
4 8 
some of the end-product regulation by the neuronal dopamine pool. 
Direct dopamine agonists, as dopamine and apomorphine, do in fact 
cause a partial inhibition of the lesion-induced increase in tyrosine 
hydroxylase activity, presumably by allowing calcium influx through 
their interaction with presynaptic dopamine receptors. That this 
inhibition of tyrosine hydroxylase activity is mediated via presynaptic 




blockers, such as haloperidol, to block the apomorphine effect. *' 5 
Dopamine and apomorphine have also been shown to inhibit the synthesis 
of dopamine in rat striatal synaptosomes, a medium of the synaptic 
terminals in which only local responses are measured.^ 
Further support for the role of presynaptic receptors in the 
regulation of dopamine synthesis comes from the observations (1) that 
the dopamine receptor blockade with haloperidol will increase tyrosine 
hydroxylase activity beyond that maximally obtained by stimulation 
alone, and (2) that iontophoretically applied dopamine to the nigro- 
striatal dopamine neurons in the pars compacts inhibits firing of 
the dopamine neurons, possibly by reacting with dopamine autoreceptors 
on the cell body, a similar decrease in activity to that obtained with 
48 
dopamine agonists in presynaptic dopamine receptor studies. 
Cholinergic Contribution to the Extrapyramidal System: 
Cholinergic neurons appear to play an important role in the 
extrapyramidal system. The highest concentrations in the brain of 
choline acatylase and acetylcholinesterase, the enzymes responsible 
for synthesis and degradation, respectively, of acetylcholine are 
6 36 37 
found in the caudate and putamen. * * Correspondingly, the caudate 
contains the highest number of muscarinic receptors, with the putamen 
26 
and globus pallidus containing an intermediate amount. Both afferent 
nigrostriatal cholinergic fibers"^ and efferent cholinergic striato- 
42 
pallidal and striatonigral fibers have been described. Selective 
lesions disrupting these pathways, however, fail to significantly 
decrease choline acetylase or acetylcholinesterase in the striatum, 

11 
suggesting that the neostriatal cholinergic system is primarily con- 
36 37 
tained within the neostriatum as intemeurons. * Similarly, although 
lower levels of these enzymes are found in the substantia nigra, the 
36 
levels are unchanged by lesions of the striatonigral pathway. The 
possibility, however, of substantia nigral cholinergic intemeurons 
or cholinergic input from other areas of the brain still exists. 
The execution of purposeful movement appears to be dependent upon 
a dopmainergic - cholinergic balance within the striatum. Acetyl¬ 
choline has been shown to increase, while dopamine decreases, the 
spontaneous firing rate of most cells in the caudate.^ Local injec¬ 
tions of carbachol or physostigmine into the striatum have been shown 
22 
to decrease the circling induced in rats by dopamine. Although the 
ability of antipsychotic drugs to induce Parkinsonian-like symptoms 
is related to their ability to block dopamine receptors, several anti¬ 
psychotic drugs with potent dopamine receptor blocking ability have 
been found which show a much lower incidence of extrapyramidal side 
effects than would be expected. These drugs were found to have 
antimuscarinic properties. Subsequent studies demonstrated that the 
greater the antimuscarinic potencies of these antipsychotic drugs, 
27 28 54 
the less the frequency of extrapyramidal side effects. * ’ Anti¬ 
cholinergic drugs are not only very effective clinically in counter¬ 
acting the extrapyramidal side effects of the antipsychotics, but are 
also of some benefit in Parkinson's patients and in animals with 
23 
lesions of the dopaminergic nigrostriatal pathway , while cholinergic 




There is a great deal of evidence to suggest that cholinergic 
nerves are not only involved in maintaining a balance with dopamine 
in the striatum, but also have either direct or indirect effects upon 
dopaminergic neurons themselves. Since dopaminergic activity within 
the striatum has been found to have an inhibitory effect upon cholin¬ 
ergic neurons, such that an increase in dopaminergic activity is 
associated with a decrease in cholinergic activity, and a decrease in 
46 
dopaminergic activity with an increase in cholinergic activity , it 
is not surprising that cholinergic activity in turn may affect dopa¬ 
minergic neurons. Carbachol infusion into the substantia nigra leads 
to similar changes as those caused by decreased impulse flow in the 
nigrostriatal pathway ; that is, an increase in striatal dopamine 
32 
levels by decreasing turnover without changing synthesis. Infusion 
of atropine in the substantia nigra has been shown to increase both 
32 
turnover and synthesis of dopamine , as is found with an increase in 
impulse flow. Further studies demonstrated that neurons in the zona 
reticulata are stimulated by iontophoretie acetylcholine, an effect 
which can be specifically blocked by the anticholinergic, scopolamine. 
The enhanced firing of the zona reticulata cells is associated with a 
reduced firing of cells in the pars compacta. This, plus the fact 
that acetylcholine has no effect when administered directly into the 
pars compacta, suggests that acetylcholine may be exciting neurons in 
the zona reticulata, which then form inhibitory synapses on pars 
46 
compacta cells. Although these results suggest a possible role for 

13 
cholinergic influence in the substantia nigra, they are not consistent 
with results obtained with the systemic administration of the same 
cholinergic drugs. Physostigmine, oxotremorine, and arecoline, 
given systemically, have been shown to increase release and turnover 
of dopamine, as measured by HVA levels. This effect can be counter¬ 
acted by the systemic administration of atropine.^^ Although some 
studies investigating the effect of anticholinergic drugs on turnover 
41 44 
rate of dopamine have noted a significant decrease in HVA levels ’ , 
most studies have found either no change or only a slight decrease (1) 
2 12 
in the rate of disappearance of dopamine after a-methy1-p-tyrosine * , 
2 12 1 
(2) on the endogenous levels of dopamine ’ ’ , or (3) on HVA 
40 
levels. The results obtained from the systemic use of the cholinergic 
and anticholinergic drugs are more consistent with the effects of these 
drugs when given intrastriatally. Perfusion of the caudate with ace¬ 
tylcholine plus physostigmine was found to increase the release of 
g 
dopamine , while microinjections of atropine in the caudate were found 
to have no effect on HVA levels.^ 
Substantial evidence has accumulated for the existence of pre- 
synaptic cholinergic receptors on adrenergic nerve terminals outside 
the central nervous system. Regulation of the release of norepineph¬ 
rine from adrenergic nerves by inhibitory muscarinic and stimulatory 
nicotinic receptors have been demonstrated, the muscarinic receptors 
being approximately 2 to 3 times more sensitive to acetylcholine than 
19 
the nicotinic receptors. It is, therefore, possible that such 
cholinergic presynaptic receptors may be present on dopamine terminals, 

14 
affecting the release of dopamine. In support of this is the recent 
finding that in striatal slices acetylcholine inhibits the release of 
^H-dopamine induced by electrical or KC1 stimulation.^ These results 
are similar to those found in peripheral adrenergic nerves with regard 
to inhibitory muscarinic receptors. However, it has also been demon¬ 
strated that perfusion of the caudate with oxotremorine or acetyl¬ 
choline plus physostigmine increases, rather than decreases, release 
g 
of striatal dopamine. Prior to this, benztropine and other anti¬ 
parkinsonian anticholinergic and antihistaminic drugs were shown to 
14,20,52 
inhibit the reuptake of dopamine in striatal synaptosomes and 
into dopaminergic neurons in vivo.^ Since the ability to block re¬ 
uptake of dopamine appeared to coincide with their relative clinical 
potencies in treating Parkinsonian extrapyramidal symptoms, it was 
suggested that the beneficial effect of these drugs was due to their 
ability to inhibit reuptake of dopamine, making more dopamine available 
in the synaptic cleft, rather than, or in addition to, their anti¬ 
cholinergic properties. This is not supported clinically, however, 
in that atropine and scopolamine, which are active anti-Parkinson's 
20 52 
agents, demonstrate little or no ability to block dopamine reuptake ’ , 
and in that atropine, as well as benztropine, has been shown to poten¬ 
tiate the Dopa and apomorphine induced increase in locomotion in 
20 
rats. Further biochemical studies also tend to support a feedback, 
as opposed to a local, cholinergic mechanism for the effects seen in 
dopaminergic neurons. Anticholinergics have been shown to reduce the 
phenothiazine or haloperidol induced increase in dopamine turnover, 

15 
as measured both by the rate of disappearance of dopamine from the 
2 12 9 
striatum * and by the HVA levels. Since this effect is seen in 
the face of dopamine receptor blockade, it is presumed to take place 
beyond the receptor and is postulated to involve an inhibition of 




Although little norepinephrine is contained within the striatum, 
approximately l/50th to l/100th the concentration of dopamine, there 
is some feeling that this transmitter may play an important role. 
This is based upon the observations that (1) L-Dopa which is also a 
precursor of norepinephrine via dopamine is more effective in pro¬ 
ducing locomotor hyperactivity than apomorphine, a specific dopamine 
agonist, and (2) L-Dopa is not as effective if the formation of nor¬ 
epinephrine by dopamine 3-hydroxylase is inhibited. It is therefore 
possible that the noradrenergic system, while not directly involved, 
is playing a regulatory role in determining the sensitivity of the 
extrapyramidal system to dopamine. More work is necessary in this 
29 
area, however, before this can be established. 
GABA-ergic Neurons: 
It appears likely that GABA-ergic (gamma amino butyric acid) 
neurons have an important inhibitory function in the substantia nigra 
and possibly also play a role in the striatum. Evidence for a GABA- 
ergic role in the substantia nigra includes: (1) in the brain, GABA 

16 
and its synthesizing enzyme, glutamic acid decarboxylase, are found 
46 
in highest concentrations in the substantia nigra; (2) lesions of 
the strionigral pathway markedly decrease both GABA and glutamic 
acid decarboxylase in the substantia nigra;^ (3) electrical stimula¬ 
tion of the caudate blocks the firing rate of nigral units in the 
8 
zona reticulata; (4) iontophoretically applied GABA in the substantia 
nigra invokes the same response as electrical stimulation of the 
caudate, blocking the activity of cells in the zona reticulata of the 
8 46 
substantia nigra; * and (5) intravenous or substantia nigral ad¬ 
ministration of biculline, a GABA receptor blocker, causes an increased 
g 
release of striatal dopamine. This all lends strong support for a 
strionigral GABA-ergic system inhibitory to nigrostriatal dopaminergic 
neurons. 
There is some evidence that GABA may also play a role in the 
striatum. Labeled GABA is taken up by receptors in the striatum, 
and glutamic acid decarboxylase activity can be found in striatal 
synaptosomes, establishing the presence of GABA-ergic neurons in 
g 
the striatum. It has been demonstrated that GABA in the striatum 
causes a decrease in the release of dopamine and that the GABA 
receptor blockers, biculline and picrotoxin, cause an increase in the 
release of dopamine and are capable of counteracting the decrease 
8 
in dopamine release induced by GABA. Whether these represent feed¬ 




MODEL OF POSSIBLE NIGROSTRIATAL NEURONAL INTERACTIONS 
Motor 
Activity 
Ach = acetylcholine 
DA = dopamine 
GABA = -aminobutyric acid 
+ = excitatorv 
- = inhibitory 





To determine the effects of cholinergic and anticholinergic 
drugs on tyrosine hydroxylase activity, the dopa decarboxylase 
inhibitor, Ro 4-4602, was given to block the conversion of Dopa to 
dopamine, and a modification of the method of Kehr, Carlsson, and 
33 
Lindquist was used to assay for Dopa. In the normal untreated 
rat brain, Dopa is rapidly converted to dopamine and endogenous Dopa 
33 
levels are very low (< 10 ng/g). After Ro 4-4602, there is a 
59 
linear increase in Dopa for up to an hour. Determining striatal 
Dopa levels in an Ro 4-4602 treated rat is, therefore, a reliable 
method for measuring the effects of drugs on tyrosine hydroxylase 
activity in vivo, and thus of assessing the effective rate of 
synthesis of dopamine. 
Ro 4-4602 was given to all rats 30 min prior to kill in a dose 





Dopa Assay using 6-Hydroxydopamine Treated Rats: 
Intracistemal 6-hydroxydopamine (6-OH DA) has been shown to 
cause selective degeneration of monoaminergic neurons. When a 
norepinephrine uptake blocking drug is given prior to the 6-OH DA to 
prevent its action on noradrenergic neurons, the degeneration is 
specific for dopaminergic neurons.^’^' In order to determine the 
effects of physostigmine and benztropine on tyrosine hydroxylase 
activity in a dopamine deficient state, such as Parkinson’s Disease, 
a pilot study was carried out using 6-OH DA treated rats as an experi¬ 
mental animal model. The rats were obtained at 5 weeks of age from 
Dr. B. Shaywitz, in whose lab, 2 litters of rats had been randomly 
divided at 5 days of age into treated and non-treated groups. The 
treated rats had received 100 yg 6-OH DA intracistemally with the 
norepinephrine uptake blocker, desmethylimipramine, 25 mg/kg intra- 
peritoneally, being given 30 min prior to the 6-OH DA in order to 
protect the noradrenergic neurons. All rats used in this study were 
taken from these same 2 litters, including 3 untreated rats as 
controls. 
The rats were treated identically to those used for the other 
Dopa assays, receiving 800 mg/kg Ro 4-4602 30 min prior to kill. 

20 
Dopa Assay with GBL: 
Gamma butyrolactone (GBL) has been shown to selectively block 
impulse flow in central dopaminergic neurons and thus block the 
release of dopamine. The block of impulse flow produced by GBL 
administration causes approximately a 3-fold increase in tyrosine 
hydroxylase activity, as measured using Ro 4-4602 and the Dopa assay, 
59 results similar to that produced by axotomy. By blocking impulse 
flow, any change in the rate of synthesis, outside of that caused by 
GBL itself, would have to be mediated locally via presynaptic 
receptors on the dopaminergic nerve terminal, rather than through a 
neuronal feedback mechanism. In order to help define the site of 
action of the cholinergic and anticholinergic drugs, GBL was 
administered and striatal Dopa assayed as before. 
All rats were given 750 mg/kg GBL at 35 min and 800 mg/kg 




To determine the effects of cholinergic and anticholinergic 
drugs on impulse flow in dopaminergic neurons, a modification of the 
method of Murphy, Robinson, and Sharman was used to measure 
39 
3,4-dihydroxyphenylacetic acid (DOPAC) in rat striatum. The Dopac 
assay was selected rather than the measurement of HVA levels, which 
has been used to measure turnover of dopamine in previous studies, 
because of the more rapid and consistent response of Dopac to changes 
in dopamine degradation, and because it closely reflects changes in 
impulse flow in the nigrostriatal dopamine neurons.^ 

22 
MATERIALS AND METHODS 
Male Sprague Dawley (Charles River Co., Inc.) albino rats 
weighing between 150-350 gm were used. All drugs were given by 
intraperitoneal injection at times noted as minutes prior to kill. 
For the Dopa assay, all rats received Ro 4-4602 at 30 min prior to 
kill. The rats were killed by decapitation and the neostriatum 
(caudate and putamen) was dissected out rapidly and placed on dry 
ice. Estimations of Dopa were made on the bilateral striata of each 
rat. For the Dopac assay, estimations were also made on the 
bilateral striata of each rat. 
Control rats in the Dopa experiments received Ro 4-4602 and 
in the Dopa experiments with GBL received Ro 4-4602 and GBL. 
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Drugs used in Dopa and Dopac Experiments: 
Drugs Pharmaceutical Companies 
Anticholinergics: 
Atropine sulfate Merck & Co. 
Atropine methyl nitrite K & K Laboratories 
Scopolamine*HBr trihydrate Regis Chem. Co. 





Calif. Corp. for Biochem. Research 
Pilocaprine*HCl Merck & Co. 
Oxotremorine Sesquifumarate Aldrich Chem. Co. 
Arecoline*HBr Regis Chem. Co. 
DA Impulse Flow Blocker: 
Gamma-butyrolactone (GBL) Matheson, Coleman & Bell 
Dopa decarboxylase Inhibitor: 







The caudate pairs were weighed and homogenized in 2 ml (+2 ml 
more to wash the pestle and tube) of .4N PCA soln. containing - 50 mg 
Na2S20^ + 2 ml 10% EDTA + 10 ml 4N Perchloric acid - made up to 
100 ml with distilled H^O (made fresh for each experiment). For each 
tissue blank and recovery, half the cerebellum from an untreated 
rat was prepared in the same way. 100 ng of Dopa was added to the 
tissue recovery tubes. The homogenates were centrifuged at 
11,000 RPM and supernatants were brought to pH 2 with KOH (5N, IN, 
& .IN). Samples were then frozen overnight at -20°C. 
Column Procedure: 
Preparation of Dowex 50W, X-4, 200-400 mesh, H+: 100 g of 
Dowex was washed with 200 ml of 2N NaOH (containing 1% EDTA), stirring 
for 10 min. After allowing to separate, the liquid was poured off 
and the wash repeated. The Dowex was then rinsed with 1000 ml 
distilled H^O in the same manner, repeating until approximately the 
pH of H^O. The Dowex was washed 3 times with 100 ml 2N HC1 and 
rinsed again with 1000 ml distilled ^0 until approximately the pH 
of ^0. It was then kept stored in the refrigerator with 200 ml of 




Column preparation: A 4 cm column of Dowex was made in a 50 ml 
column containing a glass wool plug. The sides of the column were 
washed with ^0. Twenty ml of 0.1N sodium phosphate buffer (pH 6.5) 
with 0.1% EDTA was run through the column which was then rinsed with 
5 ml of H2O. 
Elution: The samples were thawed, centrifuged at 11,000 RPM 
for 10 min, and poured over the columns. The following solutions 
were run through the column and the eluates discarded: (1) 20 ml 60% 
aqueous methanol, (2) 10 ml H^O, (3) 10 ml 0.1M sodium citrate 
phosphate buffer (pH 2.5), (4) 10 ml H^O, and (5) 1 ml 0.1M sodium 
citrate buffer (pH 4.5). The Dopa was then eluted with 3 ml of the 
sodium citrate buffer. 
Fluorometric Determination of Dopa: 
Amino settings: Activating peak - 360 nm 
Fluorescence peak - 480 nm 
Slits: 1 - slit 4 mm at position 2 
2 - 3 mm 
3 - 4 mm 
4— 4 mm 
5- 3 mm 
6 - slit 4 mm at position 2 
7 - position 3 
Meter multiplier - .003 
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Treatment of samples: Samples were run in duplicate with a set 
of standards (0, 10, 25, 50, & 75 ng Dopa). The following solutions 
were placed in tubes, vortexing between additions: (1) 0.5 ml 0.15M 
Na^HPO^, (2) the appropriate amount of Dopa to the standards plus 
0.5 ml of 0.1M sodium citrate, (3) 0.5 ml sample in the appropriate 
tubes, (4) 0.2 ml 95% ethanol, (5) 0.05 ml 0.2% ZnSO , (6) 0.05 ml 
4 
0.1% K^FeCCN)^ - addition timed so that 6 min later 0.5 ml of 5N NaOH 
with 1% ascorbic acid (made fresh just prior to step #6) was added. 
The samples were read between 3 min and 30 min after adding the NaOH. 
Treatment of Data: 
• Using the % Transmission (T) obtained from the standards 
(subtracting the blank from the standards), a graph of % T vs. ng 
Dopa was plotted. The % T of the tissue blanks (approximately 1% 
T greater than the standard blanks) was subtracted from that of the 
samples and the amount of Dopa in the sample determined from the 
graph. The ng Dopa/g tissue was obtained by multiplying by 6 (to 
find the total amount of Dopa eluted), and dividing by the % recovery 





The caudate pairs were weighed and homogenized in 2 ml (+1 ml 
to rinse the pestle and tube) of cold 0.1N HC1. Tissue blanks and 
recoveries (containing 100 ng Dopac/tube) were prepared from half a 
cerebellum/tube. 0.12 ml cone. PCA (perchloric acid) and approxi¬ 
mately 1.4 g KC1 was added to the tubes, which were then centrifuged 
at 10,000 RPM for 10 min. The supernatant was poured into prechilled 
tubes containing 7 ml butylacetate (Baker's Superior Grade - 
redistilled) and approximately 0.4 g KC1. After capping and shaking 
in the cold room for 10 min, the tubes were centrifuged in the 
International Centrifuge at 15 RPM for 5 min. Six ml of butyl- 
acetate was drawn off the samples and added to tubes containing 2 ml 
Soln. A (see below). Four tubes for the standard curve were set up 
containing 2 ml butyl acetate and 2 ml Soln. A. After capping and 
shaking for 6 min in the cold room, the tubes were centrifuged for 
5 min at 15 in the International Centrifuge. 
Soln. A: 35 ml 1^0, 1 ml 2N HC1, 1.5 ml ethylenediamine (twice distilled) 
B: 6 ml 1^0, 6 ml cone. HC1 
C: 18 ml H^O, 2 ml ethylenediamine (EDA, twice distilled) 
Assay: 
Two tubes for use in setting the amino were prepared with 

28 
.85 ml Soln. A and 50 ng & 100 ng Dopac, respectively. Eight tubes for 
use as standards were prepared with .85 ml of the butylacetate-Soin. A 
mixtures made in the previous section (2 blanks, 2 with 25 ng Dopac, 
2 with 50 ng Dopac, 1 with 75 ng Dopac, and 1 with 100 ng Dopac). 
Samples were run in duplicate, .85 ml/tube. Marbles were used to 
cover the mouths of the tubes, which were then placed in a water 
bath at 60°C with a tight lid for 20 min. The tubes were placed in 
ice and the bucket covered. Twenty-five ml of Soln. B was added to 
each of the tubes, which were then vortexed, and the bucket recovered. 
After approximately 10 min, 25 ml of Soln. C was added, the tubes 
vortexed, and the bucket recovered. The samples were read in a dark 
room in the Aminco: activating peak - 385 nm; fluorescence peak - 
455 nm; using a Coming filter # 3389 (CS3-73, 1.52 min); slit 
settings were the same as for the Dopa Assay: Meter multiplier - .03. 
Treatment of the Data: 
Using the % Transmission (T) obtained from the standards (sub¬ 
tracting the blanks from the standards), a graph of % T vs. ng 
Dopac was plotted, the % T of the tissue blanks was subtracted from 
that of the samples, and the amount of Dopac assayed determined 
from the graph. The ng Dopac/g tissue was obtained by dividing the 
ng Dopac assayed by the fraction of sample used for the assay (36.4%), 




Data was analyzed using the Standard Estimate of the Mean (SEM) 
and a two-tailed "t" test. p < .05 is considered a significant 
difference, while p > .05 is not a significant difference. 
Dopa Assay: (Tables 1 & 2; Figures 3-6) 
Benztropine was found to be a potent and dose related inhibitor 
of Dopa accumulation. While artane, atropine, and scopolamine showed 
only slight, if any, inhibitory properties. All of the cholinergic 
drugs tested - physostigmine, pilocarpine, oxotremorine and arecoline 
significantly increased accumulation of Dopa. A better response was 
found when the drugs were given at 40 min as opposed to 45 min prior 
to kill, probably due to their shorter duration of action. All the 
anticholinergic drugs, including those having only minimal effects 
when used alone, successfully prevented or significantly inhibited 
the physostigmine induced increase in Dopa accumulation. The central 
action of these drugs was confirmed by using atropine methylnitrite 
(AMN), a peripheral anticholinergic with no central effects, which 
was shown to be ineffective in preventing the physostigmine induced 
increase in Dopa accumulation. Neither atropine nor benztropine 
were able to significantly affect the pilocarpine induced increase 




DOPA ASSAY - EFFECTS OF CHOLINERGIC AND ANTICHOLINERGIC 
DRUGS USED INDIVIDUALLY 
DRUG* 
DOSE 





Control 29 1033 + 34 
Atropine 50 60 17 928 + 31 .05 -10 
Scopolamine 25 60 3 1042 + 79 
a 
N.S. 
?! 50 60 4 895 + 91 N.S. 
Benztropine 15 60 4 779 + 44 .01 -25 








II 50 60 3 387 + 33 < .01 -63 
Artane 50 60 6 863 + 86 .05 -16 
Physostigmine 1 45 11 1661 + 77 < .01 +61 
If 1 40 7 1898 + 142 < .01 +84 
Pilocarpine 100 45 4 1271 + 152 .04 +23 
II 100 40 8 1861 + 140 < .01 +80 
Oxotremorine 3 40 3 1423 + 37 < .01 +38 
Arecoline 50 40 3 1411 + 126 < .01 +37 
* All rats received 300 mg/kg Ro 4-4602 at 30 min prior to kill 
** min prior to kill 
*** Dopa measured in ng/g of tissue. 
+ Compared with the control. 
++ Percent change in Dopa accumulation from control 
Increase - + decrease = - 




DOPA ASSAY - INHIBITION OF THE CHOLINERGIC-INDUCED INCREASE 
IN DOPA ACCUMULATION BY ANTICHOLINERGIC DRUGS 
DRUGS* 
DOSES 





Physostigmine 1 45 11 1661 + 77 
II 1 40 7 1898 + 142 
AMN4^ 
+ Physostigmine 25/1 60/40 3 2174 + 190 N.S. 
Atropine 
+ Physostigmine 50/1 60/45 15 822 + 41 <.01 .05 






















+ Physostigmine 15/1 60/40 3 1075 + 173 .02 N.S, 






Pilocarpine 100 40 8 1861 + 140 
Atropine 
+ Pilocarpine 50/100 60/40 3 1809 + 73 N.S. 
Benztropine 
+ Pilocarpine 15/100 60/40 3 1728 + 31 N.S. 
* All rats received 800 mg/kg Ro4-4602 at 30 min prior to kill. 
** min prior to kill 
*** Dopa measured in ng/g of tissue. 
+ Compared with the cholinergic drug (physostigmine or pilocarpine). 
++ Compared with the anticholinergic drug (atropine, scopolamine, 
artane, or benztropine). 
-H-4- Atropine methylnitrite, a peripheral anticholinergic which does 






















QOPA ASSAY - EFFECTS OF ANTICHOLIEERC-IC DRUGS 
FIGURE k 
DOPA ASSAY - EFFECTS OF CHOLINERGIC DRUGS 












DOPA ASSAY - INHIBITION OF PHY3OSTIGMU'IE-EIDUCEQ INCREASE 
El DOPA ACCUMULATION BY ANTICKOLETEEGIC DRUGS 
FIGURE 6 
DOPA ASSAY - ANTICHOLINERGIC DRUGS WITH PILOCARPINE 
?ilo, Pilo. ?ilo. 
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Dopa Assay Using 6-OH DA Treated Rats: (Table 3; Figure 7) 
In this pilot study, it was found that the Dopa accumulation in 
the 6-OH DA treated control rats was only about 50% that of their 
untreated littermates. With regard to drug effects in the 6-OH DA 
treated rats, benztropine produced a significant decrease, while 
physostigmine was found to produce no significant change in Dopa 
accumulation from that of the 6-OH DA control rats. 
TABLE 3 
DOPA ASSAY - USING 6-OH DA TREATED RATS 
, L/v7 J JL i i 
DRUG (mg/kg) t n D0PA(ng/g + SEM) p p^ 





6-OH DA Control 3 638 ± 35 <.01 
6-OH DA/Phys. 1 45 3 590 ± 35 N.S. 
6-OH DA/Benz. 10 60 3 364 ± 16 <.01 -43 
* All rats received 800 mg/kg Ro4-4602 at 30 min prior to kill. 
** min prior to kill 
*** Dopa measured in ng/g of tissue. 
+ Compared with control. 
4+ Compared with 6-OH DA control. 
+++ Percent change in Dopa accumulation from 6-OH DA. 














DOPA ASSAY USING 6-CH DA TREATED RATS 
Control 6-CH DA 6-OH DA 6-OH DA 




Dopa Assay with GBL: (Table 4) 
After stopping impulse flow through the dopaminergic nigrostriatal 
neurons with GBL, no change in the accumulation of Dopa could be 
produced with either the anticholinergic drugs, atropine and benztropine, 
or the cholinergic drugs, physostigmine and pilocarpine. 
TABLE 4 





t n D0PA(ng/g + SEM)''** *** 
+ 
P 
GBL Control 6 2548 + 104 
Atropine 50 60 6 2294 + 189 N.S. 
Benztropine 15 60 6 2677 + 176 N.S. 
Physostigmine 1 40 6 2457 + 293 N.S. 
Pilocarpine 100 40 3 2547 + 230 N.S. 
* All rats received 750 mg/kg GBL at 35 min and 800 mg/kg Ro4-4602 
at 30 min prior to kill. 
** min prior to kill 
*** Dopa measured in ng/g of tissue. 




Dopac Assay; (Table 5; Figure 3) 
The cholinergic drugs, physostigmine and pilocarpine, caused a 
significant: increase in Dopac levels in the striatum, while the 
anticholinergic drugs, atropine and benztropina, had no significant 
effect on Dopac levels. From the graph it appeared that benztropine 
was more effective in countering the physostigioine induced increase 
in Dopac, while atropine was more effective in countering the pilo¬ 
carpine induced increase in Dopac; however, after statistical analysis, 
all that could be said was that the physostigmine, but not the pilo¬ 
carpine, induced increase in Dopac could be inhibited by benztropine. 
Atropine did not produce a statistically significant inhibition of 



















c/ * "t* /oA 
Control 6 1218 + 66 
Atropine 50 4 1148 + 64 N.S. 
Benztropine 20 8 1192 + 37 N.S. 
Physo s tigmine 1 8 1879 + 92 <.01 +54 
Pilocarpine 100 3 1770 + 173 .02 +45 
Atropine 
+ Physostigmine 50/1 4 1588 + 141 N.S. ,05 
Benztropine 
+ Physostigmine 20/1 4 1294 + 77 <.01 N.S. 
Atropine 
+ Pilocarpine 50/100 4 1285 + 84 N.S. N.S. 
Benztropine 
+ Pilocarpine 20/100 3 1614 + 58 N.S. <.01 
* The anticholinergic drugs (atropine and benztropine) were given at 
60 min prior to kill, and the cholinergic drugs (physostigmine and 
pilocarpine) were given at 40 min prior to kill. 
** Dopac was measured in ng/g of tissue. 
+ Compared with control. 
++ Compared with the cholinergic drug, 
+++ Compared with the anticholinergic drug. 
t Percent change in Dopac accumulation from control. 




The administration of a variety of cholinergic drugs, including 
physostigmine, pilocarpine, arecoline, and oxotremorine, consistently 
produced an increase in dopaminergic activity. This stimulation of 
dopaminergic activity by cholinergic drugs involved both an increase 
in tyrosine hydroxylase activity,as measured by Dopa accumulation, 
and an increase in impulse flow,as measured by Dopac accumulation 
(with physostigmine and pilocarpine). The increase in synthesis demon¬ 
strated in this study is consistent with the recent observation by Ulus 
and Wurtman, Dec. 1976, that choline administration, which increases 
acetylcholine levels, results in an increase in tyrosine hydroxylase 
... .58 
activity m rat striata. 
While the anticholinergic drugs, atropine, scopolamine, and artane, 
had either no effect or caused only a slight decrease in tyrosine 
hydroxylase activity whan used alone, they all significantly inhibited 
the physostigmine-induced increase in tyrosine hydroxylase activity. 
Since this effect is seen with several anticholinergics, including 
atropine, which is a specific muscarinic blocking agent, the mechanism 
of action is most likely due to a blocking of the effects of the in¬ 
creased muscarinic cholinergic activity produced by physostigmine. 
The failure of these anticholinergic drugs to decrease tyrosine 
hydroxylase activity significantly in the absence of an initial choli¬ 
nergic stimulus to increase tyrosine hydroxylase activity, suggests a 
normally low cholinergic component to the striatal dopaminergic - cho¬ 
linergic balance. If the cholinergic contribution is normally low, 
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the anticholinergic drugs would be expected to have little or no effect. 
This is also consistent with the observation that anticholinergic drugs 
appear to inhibit the increase in dopaminergic activity induced by anti- 
2 9 12 
psychotic drugs. ’ ’ Since dopamine has been shown to inhibit striatal 
46 
cholinergic activity , blockade of dopamine receptors by the antipsy¬ 
chotic drugs would release the cholinergic neurons from inhibition and 
lead to an increase in cholinergic activity. This increase in choli¬ 
nergic activity would result in, or at least contribute to, the increase 
in dopaminergic activity seen following the administration of the anti¬ 
psychotic drugs. By blocking this increase in cholinergic effects, the 
anticholinergic drugs would, therefore, also be expected to inhibit 
the antipsychotic-induced increase in dopaminergic activity. This 
concept of a dopaminergic - cholinergic balance such that dopamine 
plays a primary tonic inhibitory role is also supported by the beha¬ 
vioral observation that the dyskinesia associated with intrastriatal 
dopamine is counteracted by cholinergic drugs, but is not made more 
13 
severe by pretreatment with atropine. 
There are two possible explanations for the ability of benztropine, 
but not the other anticholinergics, to decrease tyrosine hydroxylase 
23 
activity. First, benztropine may be a more potent anticholinergic , 
and thus higher doses of the other anticholinergics would be needed 
to display the same inhibitory effect produced by benztropine-. The 
other, and more likely, possibility is that benztropine affects tyrosine 
hydroxylase activity by a direct effect, independent of its cholinergic 
properties. This was suggested by Coyle and Snyder (1969) in their 
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study of the effects of benztropine on reuptake of dopamine into striatal 
14 
synaptosomes. It is still, therefore, possible that this effect is 
being mediated through benztropine's ability to decrease reuptake of 
dopamine, making more dopamine available at the postsynaptic receptor. 
This additional action of benztropine may also explain why benztropine 
is clinically more effective than the other anticholinergic drugs in 
counteracting Parkinsonian extrapyramidal symptoms. 
That neither atropine nor benztropine was able to inhibit the 
pilocarpine induced increase in tyrosine hydroxylase activity implies 
either a direct pilocarpine effect, independent of its cholinergic 
properties, or a more potent cholinergic effect, which was not counter¬ 
acted by the anticholinergics in the doses used in this study. Although, 
peripherally, pilocarpine has been found to have a complex mixture of 
2 3 
nicotinic as well as muscarinic responses , it is doubtful that the 
effects in this study were being produced by stimulation of nicotinic 
receptors. If nicotinic receptors played a role in the stimulation 
of tyrosine hydroxylase activity, physostigmine, which increases 
acetylcholine at the receptor site by inhibiting acetylcholinesterase, 
would also be expected to have both muscarinic and nicotinic effects. 
Since atropine, a specific muscarinic receptor blocker, was able to 
totally block the physostigmine-induced increase in tyrosine hydroxy¬ 
lase activity, stimulation of nicotinic receptors was apparently not 
of major importance. Pilocarpine does seem to have a cholinergic 
action which is not countered by atropine administration, since the 
activity of cholinergic neurons remains depressed even after atropine 
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administration.In addition to its central cholinergic effects, 
such as cortical arousal in cats, which can be blocked by atropine, 
23 
pilocarpine has been found to have some strychnine-like effects. 
It is uncertain, however, what part, if any, this plays in the response 
seen in this study. 
The absence of any effect on tyrosine hydroxylase activity with 
the cholinergic and anticholinergic drugs after treatment with GBL to 
block impulse flow through the dopaminergic neurons makes the possi¬ 
bility of a major presynaptic site of action for these drugs unlikely, 
at least when they are given systemically. This is supported by the 
results of the Dopac assay. The cholinergic drugs, physostigmine and 
pilocarpine, which had produced increases in tyrosine hydroxylase 
activity, also produced increases in impulse flow in the dopamine 
neurons. Atropine had no significant effect on either impulse flow 
or on tyrosine hydroxylase activity. These results suggest that the 
stimulation of tyrosine hydroxylase activity by cholinergic drugs 
involves the intact dopamine neuron and is via increased impulse flow 
rather than through presynaptic receptors. 
It has been demonstrated that microinjections of carbachol into 
the substantia nigra inhibit dopamine turnover and have no effect on 
32 
synthesis, while atropine in the substantia nigra increases turnover. 
These results are opposite to those found following the systemic use 
of the same drugs. it is therefore unlikely that the substantia 
nigra is the major site of action of the systemically administered 
cholinergic and anticholinergic drugs. On the other hand, perfusion 
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of the caudate with acetylcholine plus physostigmine or with oxotre- 
g 
morine alone was found to increase the release of dopamine and micro¬ 
injections of atropine into the caudate were found to have no effect 
40 
on HVA levels. These results are more consistent with the effects 
following the systematic use of these drugs. Although these findings 
suggest that the major site of action of the cholinergic and anti¬ 
cholinergic drugs is in the striatum with a feedback loop to the dopa¬ 
mine neurons in the substantia nigra, an extra-striatal site of action 
for these drugs cannot be ruled out. It is also still possible that 
local acetylcholine in both the striatum and the substantia nigra may 
play a role in normal regulation of dopaminergic activity, since the 
effects of systemic cholinergic and anticholinergic drugs may have a 
lower affinity for these regions of the brain, or may have more dif¬ 
ficulty gaining access to these sites as the result of local blood 
supply or diffusion. 
The results of the Dopac experiments in which the cholinergic 
drugs, physostigmine and pilocarpine, were given in conjunction with 
the anticholinergic drugs, atropine and benztropine, are difficult to 
interpret. The expected result was that the anticholinergic drugs 
would at least counteract the increase in Dopac seen with physostig¬ 
mine. This was, in fact, the case with benztropine, which did cause 
a statistically significant inhibition of the physostigmine induced 
increase in Dopac. However, because of the relatively greater range 
of error encountered in the Dopac experiments, as compared to the Dopa 
assays, no statistically significant change from the cholinergic-induced 
increase in Dopac could be seen after the addition of atropine to 
■ 
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physostigmine or either atropine or benztropine to pilocarpine treatment. 
The pilot study using rats which had been treated with intra- 
cistemal 6-hydroxydopamine in conjunction with intraperitoneal des- 
methylimipramine, to cause a selective degeneration of dopaminergic 
neurons, showed a decrease of approximately 50% in Dopa accumulation 
as compared with normal rats. These rats showed a further decrease 
in Dopa accumulation when treated with benztropine, a similar decrease 
to that seen when treating normal rats with benztropine. The 6-hydroxy¬ 
dopamine treated rats, however, were unable to increase tyrosine hy¬ 
droxylase activity when treated with physostigmine, whereas normal 
rats could. This may be a clue to the mechanism by which cholinergic 
drugs are able to exacerbate Parkinson's Disease and Parkinsonian-like 
61 
movement disorders induced by neuroleptic drugs , while normal un¬ 
treated animals and people are able to compensate for these cholinergic 
drug effects without the development of Parkinsonian symptoms. In 
Parkinson's Disease, where there is a degeneration of a large part of 
the dopaminergic neurons, the remaining neurons may already be pro¬ 
ducing dopamine optimally and be unable to increase synthesis further 
to compensate for the increase in cholinergic activity. In the neuro¬ 
leptic induced Parkinsonian-like syndrome, where there is already an 
increase in dopaminergic activity in order to compensate for the re¬ 
ceptor blockade^, it may be that the addition of cholinergic drugs is 
unable to further stimulate dopamine production, and the balance 
would thus be tipped even more in the direction of increased choli¬ 
nergic versus dopaminergic activity in the striatum. This hypothesis 




1. Using an assay for Dopa after inhibition of Dopa decarboxylase 
as a measurement of tyrosine hydroxylase activity and an assay for 
Dopac as an indicator of changes in impulse flow in nigro-neostriatal 
dopamine neurons, this study has shown that the systemic administra¬ 
tion of cholinergic drugs stimulates dopaminergic activity. The sys- 
temically administered cholinergic drugs, physostigmine, pilocarpine, 
arecoline, and oxotremorine, all significantly increased tyrosine 
hydroxylase activity. Although all of the anticholinergic drugs 
tested counteracted the physcstigmine-induced increase in tyrosine 
hydroxylase activity, atropine, scopolamine, and artane, used alone, 
had either no effect or only slightly decreased tyrosine hydroxylase 
activity. This observation was postulated to be due to a tonic inhi¬ 
bitory action of dopamine neurons on cholinergic neurons, such that 
the normal cholinergic contribution in the striatum would be relatively 
low as compared to that of dopamine. Benztropine was the only anti¬ 
cholinergic drug which, when used alone, caused a significant and dose 
related decrease in tyrosine hydroxylase activity. This effect was 
felt to be due to benztropine's ability to inhibit reuptake of dopa¬ 
mine into nerve terminals, making more dopamine available at the post- 
synaptic receptor. The possibility, however, that benztropine was 
simply a much more potent anticholinergic than the others tested 
could not be ruled out on the basis of this study. The pilocarpine 
induced increase in tyrosine hydroxylase activity was not inhibited 
by either atropine or benztropine. This pilocarpine effect was thought 
■ 
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to be due possibly to a direct cholinergic effect of pilocarpine not 
subject to atropine or benztropine inhibition. 
2. The mode of action of the cholinergic and anticholinergic drugs 
was shown to be through a neuronal feedback mechanism involving the 
entire dopamine neuron rather than through a presynaptic mechanism, 
since the actions of these drugs was dependent upon impulse flow in 
the nigrostriatal dopamine neurons. This conclusion was reached after 
the cholinergic drugs, physostigmine and pilocarpine, and the anti¬ 
cholinergic drugs, atropine and benztropine, failed to affect tyrosine 
hydroxylase activity after the cessation of impulse flow in the dopa¬ 
minergic neurons with GBL, and after physostigmine and pilocarpine 
were shown to increase the accumulation of Dopac in the striatum, an 
indication of increased impulse flow in the nigro-neostriatal dopamine 
neurons. Based on previous work with intrastriatal injections of cho¬ 
linergic and anticholinergic drugs, which showed similar changes to 
those found with the systemic use of these drugs in this study, it was 
postulated that the site of action may be within the striatum and 
mediated by a neuronal feedback to the dopaminergic nerve cell bodies 
in the substantia nigra. The possibility , however, of an extra-striatal 
site of action for these drugs with a neuronal input system to the 
substantia nigra cannot be ruled out by this study. 
3. 6-Hydroxydopamine treated rats, used as a possible animal model 
of Parkinson's Disease, responded in the same way as normal rats to 
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benztropine, by decreasing tyrosine hydroxylase activity; however, 
they were unable to increase tyrosine hydroxylase activity after 
treatment with physostigmine, as normal rats did. This inability to 
increase dopaminergic activity in order to compensate for increased 
cholinergic input was suggested as the explanation for the ability 
of cholinergic drugs to exacerbate Parkinsonian extrapyramidal symptoms. 
It therefore appears that there is a balance of dopaminergic - 
cholinergic activity with respect to striatal impulse outflow, with 
each of the systems not only under feedback regulation of their own 
neurotransmitters, but also under the influence of each other’s acti¬ 
vity. The cholinergic neurons are influenced by tonic inhibitory 
dopaminergic activity, while the dopamine neurons are, in turn, affected 
by stimulatory cholinergic activity, with all systems working to 
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